Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.
about
Evaluation of the clinical efficacy of asenapine in schizophreniaEffects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the ratStructural Basis for Molecular Recognition at Serotonin ReceptorsDrug models of schizophreniaSynthesis and evaluation of a series of 2-substituted-5-thiopropylpiperazine (piperidine)-1,3,4-oxadiazoles derivatives as atypical antipsychoticsStructure and function of serotonin G protein-coupled receptors.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Molecular targets for treating cognitive dysfunction in schizophrenia.5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine.Constitutive dimerization of human serotonin 5-HT4 receptors in living cells.Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas.The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression.Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivoUsing psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.Indolealkylamines: biotransformations and potential drug-drug interactionsNewer molecules in the treatment of schizophrenia: A clinical updateThe expanded biology of serotonin.Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.Alzheimer's disease and age-related memory decline (preclinical)Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment.Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology.Serotonin modulation of cortical neurons and networks.Effect of Alkaloids Isolated from Phyllodium pulchellum on Monoamine Levels and Monoamine Oxidase Activity in Rat Brain.Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meetingFluoxetine (prozac) and serotonin act on excitatory synaptic transmission to suppress single layer 2/3 pyramidal neuron-triggered cell assemblies in the human prefrontal cortex.The serotonergic system and cognitive functionElucidation of Molecular Mechanism(s) of Cognition Enhancing Activity of Bacomind®: A Standardized Extract of Bacopa Monnieri.Serotonin contracts the rat mesenteric artery by inhibiting 4-aminopyridine-sensitive Kv channels via the 5-HT2A receptor and Src tyrosine kinase.Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.The treatment of cognitive impairment in schizophrenia.Role of serotonin in Alzheimer's disease: a new therapeutic target?Management of schizophrenia: clinical experience with asenapine.Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series.Influence of serotonin transporter gene polymorphisms on cognitive decline and cognitive abilities in a nondemented elderly population.A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment.Clozapine effects on adenylyl cyclase activity and serotonin type 1A receptors in human brain post-mortem.Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies.Association study of a functional MAOA-uVNTR gene polymorphism and cognitive function in healthy females.
P2860
Q24630385-13044108-2999-4C27-B15A-2F06B078DBF9Q24651957-6FC7C156-BA9A-4946-80FE-CD43334F5AF9Q27676926-BCACCFF8-0E12-4EC2-A05A-4F7D83D7D9AFQ28084198-DBA0C37F-B663-446E-892E-54A515027494Q28483019-E1A9196B-821E-4027-92F5-E02EAB67E737Q30382524-A143B01C-9057-4E7B-91B9-C4F685754B6CQ30489404-ECA9668B-FBF5-4880-A8E7-34FBB072F2FEQ30491310-6FF90529-F0BC-4C90-982D-D2FB1B9F1CB1Q30491992-4BF76FFE-0E3C-427F-A771-27B235D4C45BQ33292564-8484EAEA-8501-4254-A410-86CFBB46C652Q34313092-630264C9-F03E-4496-AAC6-3D12AE260F79Q34335586-7E638DB5-11FD-48D7-B0A0-51DA36874518Q34402623-594F69C1-A752-46F9-A412-BE3B29B9DCCDQ34465159-E6040ABD-7A38-4C61-871A-CED7CA2A43A6Q34559591-A5023091-232E-4B81-9D46-1A3775595350Q34775667-2D1F29D0-95F8-47A8-97A3-D21EDC97D30AQ34843883-2BE9E9B2-5A1B-472C-B8D0-9E44659BE00AQ34993925-4D1B39BF-6077-4808-8417-677CDF637115Q34996934-57464F64-847E-4AE3-BF41-1D3EC2D7E608Q35041190-F32D3FB2-F8E2-478B-98CB-9F40023E99D2Q35769113-40EE8C88-5D05-4811-855D-3EF5393D4E73Q36726602-6466BC87-9E82-45B6-BADF-C5138C271AF2Q36778507-1CAA8DC3-D398-48E2-88CC-2B9605474B9EQ36855469-8D465B08-B2EB-47C8-A049-E99A0F9EB7D0Q36881172-52E96ED1-D2C4-48FF-9C49-44941ABB4326Q37100367-73F5F50D-564B-42A4-8AB9-6B23B7819946Q37117505-C9E2D3CA-DE82-446E-89C7-68D1E858BF01Q37245282-534884F3-6F01-4EF9-93D3-58CD7A2E54CBQ37346425-877A6BB0-EBBA-42E1-B66D-CF9ABDA1A23AQ37432060-A11E1B60-0AE5-4BD2-8B68-B11C4C62D8E3Q37614697-DF3CEF94-F115-4388-819D-61F69B8511FDQ37813206-6E9E0334-F3CB-4FA9-B2F0-E8382CD5D35AQ37922766-4F5DFB96-FEFC-4FB9-8301-0A544E1FE6A8Q38093729-FA37E756-E79D-4C51-93CD-E8361E1FDE70Q38236045-09269253-A96A-457A-A54F-AF6ED12B12F5Q38413138-C161F30A-571C-49C8-AF50-07F37D13E960Q38955981-65BBB8D6-3A82-4797-9A9B-66B1B45F51C0Q39271592-078F65CB-D685-4293-B0CC-C83DA836CA08Q40346338-89F7BF0B-13AB-44B4-B84C-D777A5109EC7Q40409266-816B4D43-693D-44D3-B9F4-9D96FA4C9452
P2860
Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Serotonin receptors represent ...... zophrenia and other disorders.
@ast
Serotonin receptors represent ...... zophrenia and other disorders.
@en
type
label
Serotonin receptors represent ...... zophrenia and other disorders.
@ast
Serotonin receptors represent ...... zophrenia and other disorders.
@en
prefLabel
Serotonin receptors represent ...... zophrenia and other disorders.
@ast
Serotonin receptors represent ...... zophrenia and other disorders.
@en
P2093
P1433
P1476
Serotonin receptors represent ...... zophrenia and other disorders.
@en
P2093
Andrew E Blum
Bryan L Roth
S Mohammad Hanizavareh
P2888
P356
10.1007/S00213-003-1683-8
P577
2003-12-02T00:00:00Z